Department of Health and Social Care written question – answered on 22nd February 2018.

Alert me about debates like this

Photo of Frank Field Frank Field Chair, Work and Pensions Committee, Chair, Work and Pensions Committee

To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential effect on patients with cystic fibrosis of making Orkambi available on the NHS; and if he will make a statement.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The National Institute for Health and Care Excellence (NICE) is responsible for making decisions on the clinical and cost effectiveness of treatments. These can be very difficult decisions, and are made on the basis of very careful consideration of the evidence and public consultation. After considering the feedback from its consultation, NICE issued guidance in July 2016 which did not recommend Orkambi to treat cystic fibrosis. The decision was based on the evidence and price proposal provided by Vertex at the time of the appraisal.

The guidance will be reviewed again in 2019. This review can be brought forward where there is new evidence that is likely to impact on the current recommendations, or if the company puts forward a proposal that demonstrates their drug is cost-effective.

Does this answer the above question?

Yes0 people think so

No12 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.